Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3583635 | 0.82 | CYP2A6 (0.38) | TSHRLMNA | |
| SCHEMBL979836 | 0.81 | PDK2 (0.39) | — | |
| SCHEMBL15638416 | 0.78 | GPBAR1 (0.36) | — | |
| SCHEMBL3109144 | 0.77 | LMNA (0.33) | TSHRLMNA | |
| SCHEMBL5314612 | 0.74 | CYP3A4 (0.41) | TSHR | |
| SCHEMBL81364 | 0.74 | — | — | |
| SCHEMBL82438 | 0.74 | TDP1 (0.34) | LMNA | |
| SCHEMBL15636512 | 0.74 | GPBAR1 (0.39) | — | |
| SCHEMBL15637459 | 0.73 | HSD11B1 (0.42) | TSHR | |
| SCHEMBL6591152 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 629 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024102177-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF BRAIN CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-05-16 | — | — | WO | claimed |
| WO-2024081447-A1 | EGFR INHIBITORS FOR TREATING LUNG CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-04-18 | — | — | WO | claimed |
| EP-4345101-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2024-04-03 | — | — | EP | claimed |
| WO-2023244639-A1 | METHODS OF PREDICTING CNS CANCER RESPONSE TO TREATMENT WITH EGFR INHIBITORS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-12-21 | — | — | WO | claimed |
| WO-2023239768-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION (US) | 2023-12-14 | — | — | WO | claimed |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | INCYTE CORPORATION | 2023-12-14 | — | — | US | claimed |
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-11-16 | — | — | US | claimed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | claimed |
| CN-114341124-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2022-04-12 | — | — | CN | claimed |
| CN-113811528-A | Compositions and methods for treating cancer | 加利福尼亚大学董事会 | 2021-12-17 | — | — | CN | claimed |
| US-4582906-A | REDUCED SOIL BIODEGRADATION OF THIOL CARBAMATES | STAUFFER CHEMICAL COMPANY (US) | 1986-04-15 | — | — | US | claimed |
| US-4542126-A | Pesticidally active pyrimidin-5-yl-(thio)phosphoric acid ester-amides | BAYER AKTIENGESELLSCHAFT (DE) | 1985-09-17 | — | — | US | claimed |
| US-4540429-A | 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders | STAUFFER CHEMICAL COMPANY (US) | 1985-09-10 | — | — | US | claimed |
| US-4512989-A | IMIDOESTERS OR IMIDOTHIOESTERS | HOKKO CHEMICAL INDUSTRY CO., LTD. (JP) | 1985-04-23 | — | — | US | claimed |
| EP-0062773-B1 | 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders | STAUFFER CHEMICAL COMPANY (US) | 1984-12-05 | — | — | EP | claimed |
| EP-0118864-A1 | Pyrimidinyl derivatives | BAYER AG (DE) | 1984-09-19 | — | — | EP | claimed |
| US-4391804-A | Imidazole derivatives and fungicidal composition containing the same | HOKKO CHEMICAL INDUSTRY COMPANY, LTD. (JP) | 1983-07-05 | — | — | US | claimed |
| EP-0062773-A1 | 4-Phenyl-1,2,3-thiadiazoles as herbicide extenders | STAUFFER CHEMICAL COMPANY (US) | 1982-10-20 | — | — | EP | claimed |
| US-4146386-A | Phthalic dianilides and their use as plant growth regulators | MONSANTO COMPANY (US) | 1979-03-27 | — | — | US | claimed |
| US-4016281-A | Tetralone and indanone compounds | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DT) | 1977-04-05 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364091-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER | TP53, EGFR, SLC2A1 | TSHR 3410/4885LMNA 3720/4885 |
| US-20230399342-A1 | TRICYCLIC TRIAZOLO COMPOUNDS AS DGK INHIBITORS | DGKA, DGKI, DGKG | TSHR 2904/4885LMNA 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.